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Background/aim: It has been suggested that plasma KL-6 increases in premature infants with bronchopulmonary dysplasia (BPD). We
aimed to evaluate the predictive values of KL-6 in BPD.
Materials and methods: The study was performed in preterm neonates with birthweight ≤1500 g and gestational age ≤32 weeks. Plasma
KL-6 levels were measured on postnatal days 1, 7, and 14.
Results: BPD was identified in eight of the 28 study infants. On postnatal days 1 and 7, plasma KL-6 levels were similar in infants with
BPD [on day 1: 8.9 (7.5–17.8) U/mL and on day 7: 16.8 (10.5–47.7) U/mL] and without BPD [on day 1: 10.8 (9.4–17.2) U/mL and on
day 7: 12.9 (5.8–19.3) U/mL] (P = 0.38 and P = 0.13, respectively). On day 14, KL-6 levels were significantly higher in infants with BPD
[155.2 (15.3–545.6) U/mL] than they were in infants without BPD [7.9 (7.7–15.6) U/mL] (P = 0.001). The best predictor was KL-6 levels
on postnatal day 14 (area under the ROC curve = 0.88; range 0.75–1.0; P = 0.002). At this point, KL-6 level of 59.7 U/mL showed a
specificity of 90.0% and negative predictive value of 85.7% for BPD.
Conclusion: High plasma KL-6 levels on postnatal day 14 in premature infants may predict the development of BPD.
Key words: Bronchopulmonary dysplasia, KL-6, predictive values, preterm

1. Introduction
Bronchopulmonary dysplasia (BPD) is a syndrome of
respiratory distress caused by chronic lung parenchymal
injury, occurring especially in preterm infants (1). BPD
remains a serious problem in very low birthweight (VLBW)
infants despite the use of antenatal steroids and postnatal
surfactant therapy to decrease the incidence and severity
of respiratory distress syndrome (RDS) (2,3). BPD has a
complex and multifactorial etiology, including oxygen
toxicity, preterm delivery, hypoxia/hyperoxia, infection,
and inflammation (4).
Many studies have suggested that lung inflammation
is a major contributor to the pathogenesis of BPD (5,6).
Various parameters of lung inflammation may be used to
show lung inflammation. However, most of them such as
N-terminal propeptide of type 3 collagen, SP-A, anti-SP-A
immune complexes, nitrotyrosine, soluble E-selectin,
intercellular adhesion molecule-1, allantoin, and aldehydes
are not specific for lung disease or are complicated to
measure (6). Krebs yon den Lundgen-6 (KL-6) is a mucinlike high-molecular weight glycoprotein that is classified
into cluster 9 (MUC1) of lung tumor and differentiation
antigens. It is preferentially expressed by alveolar type 2
* Correspondence: dilekdilli2@yahoo.com

cells and stimulates lung fibrosis through its action as a
fibroblast chemotactic factor (7).
There are many studies suggesting plasma KL-6 is
increased in adult patients with various types of interstitial
pneumonia, characterized by type 2 alveolar hyperplasia
and fibrosis (8–11). KL-6 has also shown to be as a useful
marker for increased alveolar vascular permeability
associated with lung injury. However, plasma KL-6 levels
are not elevated in noninterstitial lung diseases such as
bacterial pneumonia, bronchial asthma, and pulmonary
emphysema (9). Similar pathological changes seen in
interstitial pneumonia in the lung are also predominant
in BPD (7,12,13). Plasma KL-6 can be a clinically useful
early marker for BPD. However, there are few data on the
predictive characteristics of KL-6. Therefore, in the present
study, we aimed to evaluate the predictive values of KL-6
in BPD within the first days of life.
2. Materials and methods
2.1. Study population
All eligible preterm infants between May 2014 and April
2015 were prospectively enrolled in this study, specifically
neonates with birthweight ≤1500 g and gestational age ≤32
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weeks, and admitted to the neonatal intensive care unit of
Dr Sami Ulus Maternity and Teaching Hospital of Ankara,
Turkey. Exclusion criteria were maternal chorioamnionitis,
congenital heart disease, major congenital abnormalities,
or a documented chromosomal abnormality. The
preterm infants with early neonatal sepsis (defined as
occurring in the first 3 days of life) were excluded. The
infants who died of nonrespiratory causes, who did not
survive more than 4 weeks for other obvious reasons or
were discharged before reaching a postconceptional age of
36 weeks, or for whom blood samples were not obtained
on postnatal days 1, 7, and 14 were also excluded. Data
on demographic and perinatal characteristics including
sex, birth weight, gestational age, pregnancy-induced
hypertension, diabetes, premature rupture of membranes
>18 h, antenatal steroid administration, mode of delivery,
and Apgar scores were recorded. Also recorded were the
following pulmonary data: surfactant administration
for RDS, days of mechanical ventilation, and total days
of supplemental oxygen. The rates of hemodynamically
significant patent ductus arteriosus (PDA), clinical or
proven (culture positive) sepsis within 15 days after
birth, necrotizing enterocolitis (NEC) (>grade 2), and
retinopathy of prematurity (ROP) (≥stage 3) were noted.
Length of hospital stay and discharge data were also noted.
BPD was defined in accordance with the guidelines
of the National Institute of Child Health and Human
Development/National Heart, Lung, and Blood Institute
Workshop (National Institutes of Health consensus
definition) for infants born at gestational age <32 weeks,
that is, treatment with >21% oxygen for at least 28 days.
At 36 weeks’ postconceptional age, the infants were
classified as mild, moderate, or severe BPD based on the
required fraction of inspired oxygen (FiO2): mild BPD,
none; moderate, 21% to 30%; and severe, >30% or positive
pressure assistance (14).
All preterm infants received respiratory support as per
the European Consensus Guidelines on the Management
of Neonatal Respiratory Distress Syndrome in Preterm
Infants—2013 Update (15). Exogenous surfactant,
poractant alfa (Curosurf) or beractant (Survanta), was
given within the first 6 h after birth and two further doses, if
necessary. Prophylactic surfactant administration (within
15 min of birth) was given to preterm infants of <26 weeks’
gestation. Prophylaxis was also given to those with RDS
who required intubation for stabilization in the delivery
room. After extubation, the infants were administered
nasal continuous positive airway pressure. Mechanical
ventilation was used to support neonates with respiratory
failure, if required. Crossover treatment, from conventional
ventilation to high-frequency oscillatory ventilation, was
applied to neonates with refractory respiratory failure. In
general, supportive treatment during the study was at the
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discretion of the attending neonatologist, in accordance
with the unit protocols.
2.2. Blood sampling and plasma KL-6 measurement
We obtained heparinized blood samples of 0.5 mL from
the infants by venipuncture on postnatal days 1, 7, and 14
during hospitalization (mostly, we salvaged the residual
blood that was obtained for routine examinations). The
blood samples were immediately centrifuged at 3000 ×
g for 10 min at 4 ○C to obtain plasma and then stored at
−80 ○C. The KL-6 levels in plasma were measured using
a quantitative colorimetric sandwich enzyme-linked
immunosorbent assay kit (Eastbiopharm Co., Ltd.,
Hangzhou, China) in accordance with the manufacturer’s
instructions. Each sample was run in duplicate and the
mean concentration was calculated. The sensitivity of the
kit was 1.12 U/mL with an assay range of 2–600 U/mL.
2.3. Ethics
The regional ethics committee approved the study protocol
(file no: 10/765). Investigations were performed only after
parents of the study subjects provided written informed
consent.
2.4. Statistical analyses
All statistical analyses were performed using SPSS 15.0
(Chicago, IL, USA). Numerical data are expressed as median
± standard deviation (SD) or median with interquartile
range (IQR), according to the normal distribution tested
by Kolmogorov–Smirnov test. Differences in numeric
variables were assessed using Student’s t test or Mann–
Whitney U nonparametric two-tailed test, as appropriate.
Fisher’s exact test was used for the categorical variables.
Correlation between variables was analyzed by Spearman’s
test. Friedman’s test was used for one-way repeated
measurements. Logistic regressions were used to assess
the influence of demographic and perinatal characteristics
on KL-6 levels at different time points. To validate the
usefulness of KL-6 in predicting BPD, receiver operating
characteristic (ROC) curves were created at different
time points and cut-off levels were determined when a
significant result was obtained. Values of P <0.05 were
considered significant.
3. Results
The mean gestational age and birth weight of all subjects
were 28.3 ± 2.1 weeks and 1143 ± 184 g, respectively. The
male rate was 53.6%. BPD was identified in eight of the
28 infants studied. Then the subjects were classified into
two groups: BPD group (n = 8) and non-BPD group (n
= 20). BPD was mild in two infants and moderate or
severe in six. The Table shows the characteristics of the
study subjects according to the groups. Compared to the
infants without BPD, those with BPD had significantly
lower mean gestational age (P = 0.001) and birth weight
(P = 0.001), lower incidence of antenatal steroid use (P =
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Table. Clinical characteristics of the subjects with and without bronchopulmonary dysplasia.
BPD group (n = 8)

Non-BPD group (n = 20)

P-value

Maternal age (years), mean ± SD

24.6 ± 1.7

24 ± 4.6

0.71

Gestational age (weeks), mean ± SD

25.8 ± 1.1

29.3 ± 1.5

0.001

Birth weight, mean ± SD

971 ± 158

1212 ± 147

0.001

Maternal hypertension, n (%)

2 (25)

0 (0)

0.07

Maternal diabetes, n (%)

2 (25)

0 (0)

0.07

Premature rupture of membranes, n (%)

3 (37.5)

11(55)

0.67

Antenatal steroid, n (%)

3 (37.5)

20 (100)

0.001

Cesarean delivery, n (%)

3 (37.5)

16 (80)

0.06

Apgar score, median (IQR)

7 (7–8)

8 (7–8)

0.94

Mechanical ventilation (d), mean ± SD

15 (5–25)

6 (5–7)

0.02

Supplemental oxygen (d), mean ± SD

59 (42–75)

23 (20–25)

0.001

RDS, n (%)

8 (100)

16 (80)

0.29

PDA, n (%)

6 (75)

6 (30)

0.04

Sepsis, n (%)

5 (62.5)

8 (40)

0.41

NEC, n (%)

6 (75)

0

0.001

ROP, n (%)

3 (37.5)

4 (20)

0.37

Length of hospital stay, median (IQR)

67 (52–106)

47 (40–64)

0.02

Mortality, n (%)

0

0

NA

BPD: Bronchopulmonary dysplasia; RDS: Respiratory distress syndrome; PDA: Patent ductus arteriosus; NEC: Necrotizing enterocolitis;
ROP: Retinopathy of prematurity, IQR: Interquartile range, NA: Not applicable

0.001), and longer duration of mechanical ventilation (P =
0.02), with higher rates of PDA (P = 0.04), as well as longer
hospitalization (P = 0.02). None of the study subjects died.
On postnatal days 1 and 7, plasma KL-6 levels were
similar in infants with BPD [on day 1: 8.9 (7.5–17.8) U/mL
and on day 7: 16.8 (10.5–47.7) U/mL] and without BPD [on
day 1: 10.8 (9.4–17.2) U/mL and on day 7: 12.9 (5.8–19.3)
U/mL] (P = 0.38 and P = 0.13, respectively). However, on
postnatal day 14, KL-6 levels were significantly higher in
infants with BPD [155.2 (15.3–545.6) U/mL] than they
were in infants without BPD [7.9 (7.7–15.6) U/mL] (P =
0.001). KL-6 levels were significantly elevated from day 1
to 14 in the BPD group (P = 0.001), but not in the nonBPD group (P = 0.07) (Figure 1).
According to PDA grouping, on postnatal day 1, KL-6
levels were significantly higher in infants with PDA [10.8
(9.7–20.9) U/mL] than they were in infants without PDA
[8.9 (6.8–11.2) U/mL] (P = 0.01). However, on postnatal
days 7 and 14, plasma KL-6 levels were similar in infants

with PDA [on day 7: 11.3 (3.4–21.1) U/mL and on day 14:
10.3 (4.7–448) U/mL] and without PDA [on day 7: 12.9
(9.6–23.2) U/mL and on day 14: 13.4 (7.7–17.4) U/mL] (P
= 0.24 and P = 0.87, respectively).
In infants with and without NEC, KL-6 levels were
similar on day 1. However, in infants with NEC, KL6 levels
were significantly higher on days 7 and 14 [on day 7: 19.7
(16.8–56.1) U/mL and on day 14: 350.4 (119.5–545) U/
mL] compared to infants without NEC [on day 7: 12.9
(5.8–19.3) U/mL and on day 14: 8.1 (7.7–15.6) U/mL] (P
= 0.02 and P < 0.001, respectively). Similarly, on postnatal
day 14, KL-6 levels were significantly higher in infants
with sepsis [15.6 (11.5–302.6) U/mL] than they were in
infants without sepsis [7.7 (4.7–18.1) U/mL] (P = 0.007).
When analyzed at three time points, plasma KL-6 levels
were only positively correlated with gestational age on day
1 (on day 1: r = 0.45, P = 0.01, on day 7: r = −0.24, P = 0.21,
on day 14: r = –0.36, P = 0.05). We also found that total
oxygen exposure time is positively correlated with KL-6
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At the three time points the predictive values of KL-6
levels were calculated. The best single predictor was KL-6
levels on day 14 (area under the ROC curve = 0.88; range
0.75–1.0; P = 0.002) (Figure 2). At this time point, the cutoff value of KL-6 was determined as 59.7 U/mL. Using this
cut-off, sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) for BPD were
62.5%, 90.0%, 71.4%, and 85.7%, respectively.

Figure 1. Bar graph showing KL-6 levels on postnatal days 1, 7,
and 14 according to the groups.

level on day 14 (r = 0.46, P = 0.01). Although plasma KL-6
levels were similar among infants with mild and moderate/
severe BPD on days 1 and 7, these levels were higher in
infants with moderate/severe BPD on day 14 [on day 1:
10.1 (8.9–14.7), on day 7: 19.7 (16.8–56.1), on day 14: 350
(119–545)] compared to ones with mild BPD [on day 1: 7
(7.1–7.1), on day 7: 8.5 (8–8.5), on day 14: 15 (15.3–15.3)]
(P = 0.07, P = 0.07, P = 0.03, respectively).

4. Discussion
Type 2 pneumocyte hyperplasia with varying degrees of
fibrotic change occurs in BPD (16). It is suggested that
the pulmonary fibrotic process is caused by injury to
alveolar epithelium and basement membrane. During the
regenerative process, alveolar type 2 cells proliferate, cover
the injured surface, and differentiate into type 1 cells. The
regenerating type 2 cells strongly express KL-6 antigen. The
serially elevated plasma KL-6 in infants with BPD suggests
that these infants had more severe alveolar damage than
infants without BPD at least within the first month of life.
Ogihara et al. (6) showed significant elevation of plasma
KL-6 in the BPD group soon after birth, suggesting KL-6
was a predictor for the early detection of BPD. The present
study demonstrated that the serum levels of KL-6 were
serially elevated in patients with BPD from postnatal day
1 to 14, while levels did not significantly increase in those
without BPD.
In Kurotobi et al.’s study (17), normal levels of KL-6,
measured in healthy newborns on postnatal day 1, were
reported to be 134 ± 71 U/mL. Uchida et al. (18) measured
cord plasma levels of KL-6 in 75 neonates and reported the

Figure 2. ROC curve analysis of plasma KL-6 levels at three time points for
prediction of bronchopulmonary dysplasia.
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normal range of values for cord plasma KL-6 as 44.3–148.2
U/mL (median, 73.0 U/mL). In our study the median KL-6
levels were 10.8 (8.8–14.7) U/mL on postnatal day 1, for
all subjects. The normal plasma values for KL-6 of these
two studies may differ from those of our study because
different kits were used.
It was reported that meconium aspiration syndrome
(MAS), an acute chemical pneumonitis with consequent
disruption of the alveolar–capillary barrier, is also
associated with high KL-6 levels (KL-6) (17). However,
KL-6 did not increase in infants with RDS or transient
tachypnea of the newborn (TTN). It was suggested that
KL-6 might have a role as an early indicative marker
reflecting the pulmonary remodeling in MAS. Prolonged
exposure to hyperoxia may result in the formation of
the reactive products of oxygen such as superoxide,
and may assist with the progress of oxidative injuries in
patients with BPD. Increasing KL-6 levels may reflect
the exaggeration of inflammatory processes that result in
pulmonary regenerative remodeling or fibrosis, and may
indicate the transition from RDS to BPD. In recent years,
several researchers have reported that plasma KL-6 levels
in preterm infants with BPD were higher than in those
without BPD. A systematic review suggested that plasma
KL-6 levels could be useful as early markers for predicting
BPD in preterm infants (19).
Kurotobi et al. (17) demonstrated that KL-6 was
significantly elevated in patients with BPD, but KL-6 levels
in those without BPD did not change. Ogihara et al. (6)
conducted a prospective study in 135 preterm infants
<32 weeks of gestational age. They found that among 42
infants <28 weeks of gestational age, plasma KL-6 levels
were significantly higher in those with moderate/severe
BPD compared with those with no/mild BPD. They also
reported that a plasma level of 199 U/mL at 1 week or 232
U/mL at 2 weeks was an excellent predictor of moderate/
severe BPD (PPV of 83% and 80%, respectively). Wang
et al. (20) investigated predictive characteristics of KL-6
and Clara cell protein (CC16), another peripheral blood
biomarker originating from nonciliated Clara cells, for
BPD in preterm infants. They found that serum KL-6 levels
higher than 79.26 ng/mL at 14 days postpartum in preterm
infants predict the occurrence of BPD. The authors also

stated that CC16 was less predictive than KL-6 at this
time point, but KL-6 and CC16 together enhanced the
prediction. In their study, the infants with moderate/severe
BPD had higher KL-6 levels (on postnatal days 7 and 14),
while there were no significant differences in CC16 levels.
In the current study, we followed up 28 newborns <32
weeks of gestational age. Despite the small number of
subjects, plasma KL-6 levels were similar among infants
with mild and moderate/severe BPD on days 1 and 7; these
levels were higher in infants with moderate/severe BPD on
day 14. Although the predictive values of KL-6 levels were
calculated at three time points (on days 1, 7, and 14), the
best single predictor was KL-6 levels (59.7 U/mL) on day
14. Using this cut-off value, PPV and NPV for subsequent
BPD were 71.4%, and 85.7%, respectively.
In another study, Yamane et al. (21) showed that infants
of earlier gestational age, exposed to longer mechanical
ventilation, and with reduced pulmonary function had
higher serum KL-6 levels. However, they did not show
a significant relationship between serum KL-6 level and
pulmonary functions at any postnatal age. They explained
that serum KL-6 level was not always a reliable marker of
the clinical course of BPD. We observed that total oxygen
exposure time was only positively correlated with KL-6
level on day 14.
Our results in the current study may be considered
limited by the relatively small sample size, which could
have missed small but clinically relevant differences in
some of the clinical outcomes. Due to the small number
of subjects, we do not have sufficient data to explain the
differences between KL-6 levels in preterm infants with
and without BPD from the first to the third measurement.
The fact that our results are not consistent with the
previous research may be caused by several reasons such
as sample size, ELISA kit, detection methods, and possible
confounding factors.
In conclusion, in this study, we evaluated whether
plasma KL-6 might be a predictor of BPD development.
Given the high predictive value of the 14th day KL-6 levels
in our results, KL-6 seems to be an early marker in BPD.
Further studies are required for a better understanding of
the biochemical and regulatory roles of KL-6 in preterm
infants
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